American Cancer Society2025EN
American Cancer Society Report on the Status of Cancer Disparities in the United States, 2025
Zusammenfassung
CA Cancer J Clin. 2025 Dec 16;76(1):e70045. doi: 10.3322/caac.70045 American Cancer Society’s Report on the Status of Cancer Disparities in the United States, 2025 Farhad Islami Farhad Islami, MD, PhD 1 Surveilliance, Prevention, and Health Services Research, American Cancer Society, Atlanta, Georgia, USA Find articles by Farhad Islami 1,✉, Gladys Arias Gladys Arias, MPA 2 American Cancer Society Cancer Action Network, Washington, District of Columbia, USA Find articles by Gladys Arias 2, Dongju
Kerninformationen
Email: farhad.islami@cancer.org ✉Corresponding author. Received 2025 Oct 10; Accepted 2025 Oct 10; Issue date 2026 Jan-Feb. © 2025 The Author(s). CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society. This is an open access article under the term...
Mortality from all cancers combined was 21% higher in nonmetropolitan than in large metropolitan counties, with the greatest differences for lung (45%) and cervical (36%) cancers and the smallest for prostate, female breast, and pancreatic cancers (7%–8%). By congressional district, the highest canc...
The latter included all cancers combined and four leading causes of cancer death in each sex, i.e., cancers of the lung and bronchus (lung), female breast (breast), prostate, colorectum, and pancreas, all of which except pancreatic cancer are recommended for screening in average‐risk populations, as...
Fragen zu diesem Thema?
ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.
Jetzt auf ClariMed suchenVerwandte Leitlinien
American College of Gastroenterology (ACG)2021
ACG: Colorectal Cancer Screening
American Diabetes Association2026
ADA Standards of Care in Diabetes 2026: Chapter 1 - Improving Care and Promoting Health in Populations
American Journal of Nephrology2025
Evaluating Urinary Biomarkers for Early Detection of Kidney Damage in Immune Checkpoint Inhibitors-Treated Patients
CPT: Pharmacometrics & Systems Pharmacology2025
Exposure–Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors
Digestion2025